SOMA 250 CIV
Generic Name and Formulations:
Carisoprodol 250mg; tabs.
Mylan Specialty L.P.
Indications for SOMA 250:
Relief of acute, painful musculoskeletal conditions.
≥16yrs: 250mg–350mg 3 times daily and at bedtime. Max 2–3 weeks.
<16yrs: not established.
Renal or hepatic dysfunction. Drug abuse. Pregnancy. Nursing mothers.
Muscle relaxant (central).
Sedative effects potentiated by alcohol, other CNS depressants. May be potentiated by CYP2C19 inhibitors (eg, omeprazole, fluvoxamine). May be antagonized by CYP2C19 inducers (eg, rifampin, St. John's Wort).
Dizziness, drowsiness, headache, GI upset, rash, tachycardia, orthostatic hypotension; rare idiosyncratic reactions (see full labeling).
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Chronic Spinal Pain and Depression: Does One Represent a Risk Factor for the Other?
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- Persistence of Post-Traumatic CRPS Associated With Initial Pain Sensitization
- Comparable Incidence, Intensity of Tourniquet Pain With Infraclavicular, Axillary Brachial Plexus Blocks
- Many Patients Withhold Information From Clinicians
- Shifting Pattern Seen for Primary Care Office Visits
- Questionnaire Reliably Predicts Effect of Migraine on Work-Related Duties
- Clinicians Must Do Their Part to Address Inaccurate Online Health Information